中
Home
About TUL
Group Introduction
Executive Directors
Subsidiaries
Contact Us
Innovation in R&D
R&D Pipeline
R&D Platform
R&D Updates
News
TUL Highlights
Product Center
Finished Products
Comprehensive Health Products
APIs and Intermediates
Animal protection products
Empty capsule
Medical device
Cosmetic Peptide Series
Sustainability
Enhancing Governance
Normalizing Healthiness
Brand Building
People-Oriented
Green Development
ESG Reports
ESG News
Investor Relations
News
TUL Highlights
2026-07-15
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT SODIUM HYALURONATE EYE DROPS WITH NEW SPECIFICATION
Learn More
2026-07-03
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT TADALAFIL TABLETS
Learn More
2026-06-22
Tsoi Hoi Shan Attended Novo Nordisk Roundtable to Discuss the Global Impact of Chinese Innovation
Learn More
2026-06-12
APPROVAL FOR CLINICAL TRIAL OF THE GROUP’S PRODUCT TUL321 CAPSULES
Learn More
2026-05-20
APPROVAL FOR CLINICAL TRIAL OF GROUP’S PRODUCT TUL108 FOR INJECTION
Learn More
All News
Select Year
2026
2025
2024
APPROVAL FOR CLINICAL TRIAL OF UBT37034 FOR INJECTION ON INDICATION OF OVERWEIGHT OR OBESITY
2025-10-20
TUL was awarded the 'Best ESG Pioneer Practice Listed Company Award'
2025-10-20
TUL the sterile active pharmaceutical ingredient of Ampicillin Sodium obtained the European Pharmacopoeia Compliance Certificate (CEP Certificate) issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM)
2025-10-20
TUL held its 2025 Mid-Year Results Press Conference in Hong Kong
2025-10-20
The United Animal Healthcare (Inner Mongolia) Co., Ltd. successfully obtained the new version of the Veterinary Drug GMP certificate issued by the Department of Agriculture and Animal Husbandry of the Inner Mongolia Autonomous Region
2025-10-20
TUL® AMOXICILLIN® once again received the industry's highest honor, the 'CPEO Gold Award'
2025-10-20
The 10th anniversary celebration of The United Animal Healthcare (Inner Mongolia) Co., Ltd. along with the launch ceremony of Enrofloxacin and the 8th International Forum on Clinical Applications and Prospects of Veterinary Beta-Lactamase Inhibitors, was held
2025-10-20
The three core production lines of Lianmu Veterinary Pharmaceutical Company passed the GMP on-site acceptance.
2025-10-20
TUL won two awards at the 7th China Pharmaceutical Industry Expo (CMC-CHINA 2025), namely \"2025 Top 30 Active Pharmaceutical Ingredients Business\" and \"2025 Top 101 China Pharmaceutical Industry\"
2025-10-20
Prev
1
...
5
6
7
8
9
...
17
Next
WeChat
Official
Account
To Top